← Tonghua Dongbao Pharmaceutical overview

Tonghua Dongbao Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Tonghua Dongbao Pharmaceutical Co Ltd (600867.CG)

Q3 2026
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

August 2026
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

Latest
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.